These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19404957)

  • 41. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
    Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J
    Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
    J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study.
    Roman-Blas JA; Castañeda S; Cutolo M; Herrero-Beaumont G
    Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1588-93. PubMed ID: 20556817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E; McKenna F; Vencovsky J; Valente R; Goel N; Vanlunen B; Davies O; Stahl HD; Alten R
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
    Stock TC; Bloom BJ; Wei N; Ishaq S; Park W; Wang X; Gupta P; Mebus CA
    J Rheumatol; 2012 Apr; 39(4):720-7. PubMed ID: 22382341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
    Ishiguro N; Yamamoto K; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Hara M;
    Mod Rheumatol; 2013 May; 23(3):430-9. PubMed ID: 22833377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
    Mease PJ; Gladman DD; Keystone EC;
    Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
    Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.
    Genovese MC; Yang F; Østergaard M; Kinnman N
    Ann Rheum Dis; 2016 Nov; 75(11):1979-1983. PubMed ID: 27084959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.